Big Call Screening: Johnson & Johnson, Iberdrola, AXA, Northrop Grumman
Reading Time: 3 minutes
Johnson & Johnson (JNJ) is one of the most promising long-term stories among the big caps in the medical technology and pharmaceutical sector. In addition to numerous blockbusters in the oncology segment and in the growth market for inflammatory diseases, the company is also a leader in growth areas of medical technology such as calcified heart and leg arteries (Shockwave), pulsed field ablation for cardiac arrhythmias (Varipulse), and ophthalmology. The new surgical robotics platform OTTAWA offers excellent growth opportunities, as after its...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
